SELTOLZA

Mark For: SELTOLZA® trademark registration is intended to cover the categories of cell therapy pharmaceutical preparations; immunotherapy preparations; T-cell receptors; immunotherapy preparations comprising engineered T-cell receptors; immunotherapy preparations comprising genes encoding engineered T-cell receptors. [all]

Status

2021-07-06 UTC
⟳ Refresh

LIVE APPLICATION Awaiting Examination

Research	OneLook Acronym Finder
Serial Number	90807080
Registration Number	6807011
Mark Literal Elements	SELTOLZA
Mark Drawing Type	4 - STANDARD CHARACTER MARK
Mark Type	TRADEMARK. SERVICE MARK
Register	PRINCIPAL
Current Location	NEW APPLICATION PROCESSING 2021-07-05
Basis	44(d)
Class Status	ACTIVE
Primary US Classes	005: Adhesives 006: Chemicals and Chemical Compositions 018: Medicines and Pharmaceutical Preparations 044: Dental, Medical and Surgical Appliances 046: Foods and Ingredients of Foods 051: Cosmetics and Toilet Preparations 052: Detergents and Soaps
Primary International Class	005 - Primary Class (Pharmaceuticals) Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
Filed Use	No
Current Use	No
Intent To Use	No
Filed ITU	No
44D Filed	Yes
44E Current	No
66A Current	No
Current Basis	No
No Basis	No
Domestic Representative	Christiane Campbell
Attorney Name	Christiane Campbell
Attorney Docket Number	K0677-00076

Timeline

IC 005. US 005 006 018 044 046 051 052. G & S: Cell therapy pharmaceutical preparations; immunotherapy preparations; T-cell receptors; immunotherapy preparations comprising engineered T-cell receptors; immunotherapy preparations comprising genes encoding engineered T-cell receptors
IC 044. US 100 101. G & S: Cell therapy medical treatment services; immunotherapy services; medical treatment and immune-therapy comprising harvesting a patient's white blood cells, combining white blood cells with an engineered T-cell receptor therapeutic, transducing the white blood cells with the gene encoding the engineered T-cell receptor and infusion of the transduced white blood cells back into the patient